Arthritis in Systemic Lupus Erythematosus : From 2022 International GISEA/OEG Symposium
Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations' development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients' quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 20 vom: 12. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ceccarelli, Fulvia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arthritis |
|---|
| Anmerkungen: |
Date Revised 30.10.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11206016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34808742X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34808742X | ||
| 003 | DE-627 | ||
| 005 | 20231226035350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11206016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM34808742X | ||
| 035 | |a (NLM)36294337 | ||
| 035 | |a (PII)6016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ceccarelli, Fulvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arthritis in Systemic Lupus Erythematosus |b From 2022 International GISEA/OEG Symposium |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations' development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients' quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Jaccoud’s arthropathy | |
| 650 | 4 | |a arthritis | |
| 650 | 4 | |a rhupus | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Govoni, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Piga, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Cantatore, Francesco Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Cauli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Favalli, Ennio Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Gremese, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Caporali, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraccioli, Gian Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Lapadula, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 20 vom: 12. Okt. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:20 |g day:12 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11206016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 20 |b 12 |c 10 | ||